Envista (NVST) Q2 2024 earnings summary

Executive summary

• Q2 2024 sales were $633.1M, with core sales declining 3.2% year-over-year and a net loss of $1,151.6M driven by a $1,153.8M non-cash goodwill and intangible asset impairment.

• Adjusted EBITDA margin dropped to 10% from 19.1% year-over-year, with adjusted EBITDA at $63.0M, impacted by one-time and non-cash charges.

• Free cash flow improved 41% to $86.3M, driven by improved collections, vendor management, and working capital discipline.

• Leadership changes and strategic investments in Spark manufacturing and high-margin businesses were made to reposition for future growth.

• Full-year guidance reinstated: -1% to -4% core growth and 10%-12% adjusted EBITDA margin, with a return to growth expected in Q4.

Financial highlights

• Reported sales decreased 4.4% year-over-year; core sales declined 3.2%.

• Adjusted gross margin was 54.2%, down from 57.9% year-over-year; GAAP gross margin dropped to 51.6%.

• Adjusted diluted EPS was $0.11, down from $0.43 in Q2 2023.

• Spark revenue deferral and dealer inventory realignment negatively impacted sales by $28M combined.

• SG&A expenses rose to $302.5M (47.8% of sales), up from $272.9M (41.2%).

Outlook and guidance

• 2024 core sales expected to decline 1%–4%; adjusted EBITDA margin guidance is 10%–12%.

• Q3 expected to be further impacted by one-time items, with growth expected to resume in Q4.

• Excluding one-time and non-cash charges, underlying performance is expected to be around 1% core growth and 14% EBITDA margin for the year.

• Guidance reflects ongoing improvement actions, growth investments, and macro uncertainty.

• Focus areas for 2H 2024 include accelerating Spark growth, translating Nobel Biocare investments into topline growth, and returning to consumables growth.